155 related articles for article (PubMed ID: 10668848)
1. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide pharmacokinetics in healthy young adult and elderly subjects.
Hatorp V; Huang WC; Strange P
Clin Ther; 1999 Apr; 21(4):702-10. PubMed ID: 10363735
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
4. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
Hatorp V; Oliver S; Su CA
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C
Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm.
Ruzilawati AB; Mohd Suhaimi AW; Gan SH
J Clin Pharm Ther; 2010 Feb; 35(1):105-12. PubMed ID: 20175819
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
11. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
12. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
Hatorp V; Huang WC; Strange P
J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Lefèvre G; Duval M; Gauron S; Brookman LJ; Rolan PE; Morris TM; Piraino AJ; Morgan JM; Palmisano M; Close P
Clin Pharmacol Ther; 1997 Jul; 62(1):50-9. PubMed ID: 9246019
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
16. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
17. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies.
Ruzilawati AB; Wahab MS; Imran A; Ismail Z; Gan SH
J Pharm Biomed Anal; 2007 Apr; 43(5):1831-5. PubMed ID: 17240100
[TBL] [Abstract][Full Text] [Related]
18. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
[TBL] [Abstract][Full Text] [Related]
19. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
